Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03571594 · ClinicalTrials.gov registry record · Phase 1
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Ono Pharmaceutical Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT03571594 is a Phase 1 study that was terminated before completion, run by Ono Pharmaceutical Co.. The registered enrollment target is 76 participants.
The verdict
NCT03571594, a Phase 1 study, was terminated before completion, sponsored by Ono Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-5788 in healthy adult volunteers. This study will be conducted in 4 parts: a single-ascending dose part, a multiple-ascending dose part, an elderly part and a proof of principle part.
Interventions
- DRUG Octreotide
- DRUG ONO-5788
- DRUG ONO-5788 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03571594
The ClinicalTrials.gov registry entry for NCT03571594 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Octreotide is the first listed.
NCT03571594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03571594 about?
NCT03571594 is a clinical study titled "A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers". This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-5788 in healthy adult volunteers. This study will be conducted in 4 parts: a single-ascending dose part, a multiple-ascending dose part, an elderly part and a proof of principle part.
What is the current status of trial NCT03571594?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2018-06-07. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT03571594?
The interventions under investigation include: Octreotide (DRUG), ONO-5788 (DRUG), ONO-5788 Placebo (DRUG).
Who is sponsoring clinical trial NCT03571594?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.